Registration and Sale of Proprietary Chinese Medicines Products in the Mainland
Under the guiding principles set out in the “Work Plan for Regulatory Innovation and Development of Pharmaceutical and Medical Device in the Guangdong-Hong Kong-Macao Greater Bay Area” and the “Construction Plan for the Chinese Medicine Highlands in the Guangdong-Hong Kong-Macao Greater Bay Area (2020-2025)”, Hong Kong-registered traditional proprietary Chinese medicines (pCms) for external use could be registered and sold in the Mainland through the streamlined approval procedures, thereby facilitating Mainland residents to purchase Hong Kong-registered traditional pCms, enabling Hong Kong pCm manufacturers to expand their markets, as well as creating favourable conditions for Hong Kong pCms to “go global” in the long run.
